» Articles » PMID: 36831330

Sirtuin 6-A Key Regulator of Hepatic Lipid Metabolism and Liver Health

Overview
Journal Cells
Publisher MDPI
Date 2023 Feb 25
PMID 36831330
Authors
Affiliations
Soon will be listed here.
Abstract

Sirtuin 6 (SIRT6) is an NAD-dependent deacetylase/deacylase/mono-ADP ribosyltransferase, a member of the sirtuin protein family. SIRT6 has been implicated in hepatic lipid homeostasis and liver health. Hepatic lipogenesis is driven by several master regulators including liver X receptor (LXR), carbohydrate response element binding protein (ChREBP), and sterol regulatory element binding protein 1 (SREBP1). Interestingly, these three transcription factors can be negatively regulated by SIRT6 through direct deacetylation. Fatty acid oxidation is regulated by peroxisome proliferator activated receptor alpha (PPARα) in the liver. SIRT6 can promote fatty acid oxidation by the activation of PPARα or the suppression of miR-122. SIRT6 can also directly modulate acyl-CoA synthetase long chain family member 5 (ACSL5) activity for fatty acid oxidation. SIRT6 also plays a critical role in the regulation of total cholesterol and low-density lipoprotein (LDL)-cholesterol through the regulation of SREBP2 and proprotein convertase subtilisin/kexin type 9 (PCSK9), respectively. Hepatic deficiency of Sirt6 in mice has been shown to cause hepatic steatosis, inflammation, and fibrosis, hallmarks of alcoholic and nonalcoholic steatohepatitis. SIRT6 can dampen hepatic inflammation through the modulation of macrophage polarization from M1 to M2 type. Hepatic stellate cells are a key cell type in hepatic fibrogenesis. SIRT6 plays a strong anti-fibrosis role by the suppression of multiple fibrogenic pathways including the transforming growth factor beta (TGFβ)-SMAD family proteins and Hippo pathways. The role of SIRT6 in liver cancer is quite complicated, as both tumor-suppressive and tumor-promoting activities have been documented in the literature. Overall, SIRT6 has multiple salutary effects on metabolic homeostasis and liver health, and it may serve as a therapeutic target for hepatic metabolic diseases. To date, numerous activators and inhibitors of SIRT6 have been developed for translational research.

Citing Articles

NAD enhancers as therapeutic agents in the cardiorenal axis.

Marin-Blazquez M, Rovira J, Ramirez-Bajo M, Zapata-Perez R, Rabadan-Ros R Cell Commun Signal. 2024; 22(1):537.

PMID: 39516787 PMC: 11546376. DOI: 10.1186/s12964-024-01903-4.


Inulin alleviates atherosclerosis through improving lipid metabolism, inflammation, and gut microbiota in ApoE-knockout mice: the short-chain is more efficacious.

Zhang K, Zeng Y, Li J, Huang Y, Zhang N, Gong Y Front Pharmacol. 2024; 15:1445528.

PMID: 39449970 PMC: 11499155. DOI: 10.3389/fphar.2024.1445528.


Impaired SUMOylation of FoxA1 promotes nonalcoholic fatty liver disease through down-regulation of Sirt6.

Zou D, Liao J, Xiao M, Liu L, Dai D, Xu M Cell Death Dis. 2024; 15(9):674.

PMID: 39277582 PMC: 11401847. DOI: 10.1038/s41419-024-07054-1.


The diagnostic value and associated molecular mechanism study for fibroblast-related mitochondrial genes on keloid.

Wei T, Xu Z Skin Res Technol. 2024; 30(9):e70024.

PMID: 39221860 PMC: 11367665. DOI: 10.1111/srt.70024.


Effects of (purslane) on liver function tests, metabolic profile, oxidative stress and inflammatory biomarkers in patients with non-alcoholic fatty liver disease: a randomized, double-blind clinical trial.

Milkarizi N, Barghchi H, Belyani S, Bahari H, Rajabzade F, Ostad A Front Nutr. 2024; 11:1371137.

PMID: 39135554 PMC: 11317426. DOI: 10.3389/fnut.2024.1371137.


References
1.
Min L, Ji Y, Bakiri L, Qiu Z, Cen J, Chen X . Liver cancer initiation is controlled by AP-1 through SIRT6-dependent inhibition of survivin. Nat Cell Biol. 2012; 14(11):1203-11. DOI: 10.1038/ncb2590. View

2.
Ran L, Chen Y, Zhang Z, Tao N, Ren J, Zhou L . SIRT6 Overexpression Potentiates Apoptosis Evasion in Hepatocellular Carcinoma via BCL2-Associated X Protein-Dependent Apoptotic Pathway. Clin Cancer Res. 2016; 22(13):3372-82. DOI: 10.1158/1078-0432.CCR-15-1638. View

3.
Mao Z, Hine C, Tian X, Van Meter M, Au M, Vaidya A . SIRT6 promotes DNA repair under stress by activating PARP1. Science. 2011; 332(6036):1443-6. PMC: 5472447. DOI: 10.1126/science.1202723. View

4.
Zhang W, Wan H, Feng G, Qu J, Wang J, Jing Y . SIRT6 deficiency results in developmental retardation in cynomolgus monkeys. Nature. 2018; 560(7720):661-665. DOI: 10.1038/s41586-018-0437-z. View

5.
Wang M, Lan L, Yang F, Jiang S, Xu H, Zhang C . Hepatic SIRT6 deficit promotes liver tumorigenesis in the mice models. Genes Dis. 2022; 9(3):789-796. PMC: 9243323. DOI: 10.1016/j.gendis.2020.08.007. View